by Gemma Escarré,
The EU-funded consortium GAPVAC, with members that include BCN Peptides and Barcelona's Vall d'Hebron Hospital, has conducted a clinical trial showing the positive effect of personalised vaccines for brain cancer (glioblastoma). The study was published in the journal Nature.
BCN Peptides' role in this consortium has been to manufacture the GMP peptides library to produce the vaccine used in the trial.
BCN Peptides believes personalised medicine is a strategic field. "We've been working intensely to come up with solutions to the challenges of manufacturing the active ingredients and the ad-hoc formulation for each patient," explained Dr Jordi Piró, sales manager for the company located in Sant Quintí de Mediona (Barcelona) and a CataloniaBio & HealthTech member.